Novo (NYSE: NVO) has tapped the Swedish drug-delivery developer Nanexa to develop long-acting injectable platforms for its peptide meds, with a global licensing deal worth €1.165 billion, or about $1.32 billion U.S. The deal will support up to five R&D programs targeting monthly and quarterly injections, as the drugmaker looks to extend the reach of […]
